These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9101212)

  • 1. Effect of androgen deprivation therapy on local symptoms and tumour progression in men with metastatic carcinoma of the prostate.
    Smith JA; Janknegt RA; Abbou CC; de Gery A
    Eur Urol; 1997; 31 Suppl 3():25-9. PubMed ID: 9101212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).
    Bertagna C; De Géry A; Hucher M; François JP; Zanirato J
    Br J Urol; 1994 Apr; 73(4):396-402. PubMed ID: 8199827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group.
    Janknegt RA
    Cancer; 1993 Dec; 72(12 Suppl):3874-7. PubMed ID: 8252507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
    Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
    J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies.
    Hucher M; de Gery A; Bertagna C
    Cancer; 1993 Dec; 72(12 Suppl):3886-7. PubMed ID: 8252510
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
    Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
    N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update.
    de Reijke T; Derobert E;
    Eur Urol; 2002 Aug; 42(2):139-46. PubMed ID: 12160584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review.
    Du Plessis DJ
    Urology; 1991; 37(2 Suppl):20-4. PubMed ID: 1992599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial pneumonitis associated with neoadjuvant leuprolide and nilutamide for prostate cancer.
    Wieder JA; Soloway MS
    J Urol; 1998 Jun; 159(6):2099. PubMed ID: 9598539
    [No Abstract]   [Full Text] [Related]  

  • 10. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
    Kassouf W; Tanguay S; Aprikian AG
    J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. French multicentre trial comparing Casodex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report.
    Chatelain C; Rousseau V; Cosaert J
    Eur Urol; 1994; 26 Suppl 1():10-4. PubMed ID: 7737255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].
    Abbou CC; Lucas C; Leblanc V
    Prog Urol; 1997 Dec; 7(6):984-95. PubMed ID: 9490144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
    Eastham JA; Sartor O
    J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
    Nakabayashi M; Regan MM; Lifsey D; Kantoff PW; Taplin ME; Sartor O; Oh WK
    BJU Int; 2005 Oct; 96(6):783-6. PubMed ID: 16153200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
    Cancer; 1990 Sep; 66(5 Suppl):1074-9. PubMed ID: 2203517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
    Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
    Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiandrogen monotherapy in the management of advanced prostate cancer.
    Kaisary AV
    Eur Urol; 1997; 31 Suppl 2():14-9; discussion 24-7. PubMed ID: 9074906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group.
    Dijkman GA; Janknegt RA; De Reijke TM; Debruyne FM
    J Urol; 1997 Jul; 158(1):160-3. PubMed ID: 9186345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of metastatic prostatic cancer by orchiectomy plus Anandron versus orchiectomy plus placebo. Initial results of a randomized multicenter study].
    Knönagel H; Bolle JF; Hering F; Senn E; Hodel T; Neuenschwander H; Biedermann C
    Helv Chir Acta; 1989 Aug; 56(3):343-5. PubMed ID: 2681086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved subjective responses to orchiectomy plus nilutamide (anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. International Anandron Study Group.
    Dijkman GA; Fernandez del Moral P; Debruyne FM; Janknegt RA
    Eur Urol; 1995; 27(3):196-201. PubMed ID: 7601182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.